Domain Associates

Devices & Diagnostics

Domain VC: Why we’re investing more in molecular diagnostics

When Domain Associates led Xagenic Inc.’s recent $20 million Series B, it marked the eighth diagnostics investment the firm had made with its $500 million eighth fund. The partners say they’ve invested nearly a quarter of their current fund in molecular diagnostics companies because they think genomic analysis technology has reached a tipping point. “One […]

Devices & Diagnostics

These are the most active VCs in healthcare since 2012

As investments in life science companies have dipped over the past few years, some investors have scaled back investments or walked away from the sector all together. But based on a tally by investment research firm PitchBook in its 2013 Venture Capital Healthcare Report, several firms have made 10 or more investments in pharmaceutical, medical […]

Devices & Diagnostics

VC firm Domain + Elite Consulting = new opportunities for U.S. health technology in China

While venture capitalists are usually focused on investing in innovation, this healthcare VC is turning the tables and doing some creative thinking of its own. Last week, life sciences venture firm Domain Associates unveiled an interesting partnership with Beijing-based Elite Consulting, a consulting and financial advisory firm for the Chinese pharmaceutical and medical device industry. […]

Hospitals

‘Cross-kingdom’ vaccine may protect against fungal and bacterial infections

A clinical-stage pharmaceutical company with a vaccine it says uses a single antigen to protect against both fungal and bacterial infections is looking for a series B round to fund phase 2 trials for hospital-associated infection and women’s health applications next year. NovaDigm Therapeutics’ lead product, the NDV-3 vaccine, targets the fungal infection candida and […]

News

Apnex Medical names former BSX and J&J executive as its new CEO

Apnex Medical Inc., a St. Paul-based startup developing technology to treat obstructive sleep apnea (OSA), has named Charles McKhann as its new CEO. McKhann, who previously served as a global vice president of marketing for Boston Scientific Corp.’s (NYSE: BSX) cardiac rhythm management division, replaces founder and executive director Robert Atkinson. While at Johnson & […]

News

Michigan’s Esperion Therapeutics raises $5M for cardiovascular disease drug

Esperion Therapeutics Inc., a spin-off from Pfizer Inc., has raised an additional $5 million to develop drugs that treat cardiovascular and metabolic disease, according to a SEC filing. The regulatory document states that Esperion has raised $27.75 million in equity and debt, but that dollar figure likely includes a $22.75 million Series A fundraise the company announced in 2008 after the spin-off.